LAQ 824Alternative Names: Histone deacetylase inhibitors - Novartis; NVP-LAQ824
Latest Information Update: 19 Jul 2010
At a glance
- Originator Novartis
- Class Antineoplastics
- Mechanism of Action Histone deacetylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Jul 2010 Discontinued - Phase-I for Cancer in USA (unspecified route)
- 25 May 2005 Suspended - Phase-I for Cancer in USA (unspecified route)
- 07 Dec 2004 A preclinical study has been added to the Cancer pharmacodynamics section